Global Paracetamol IV Market Growth (Status and Outlook) 2025-2031

The global Paracetamol IV market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Paracetamol when given intravenously acts as an effective treatment option in relieving pain and gives rapid relief. Moreover, the use of intravenous paracetamol in combination with NSAIDs and narcotics has been gaining popularity and acceptance, which further propels the growth of the industry.

United States market for Paracetamol IV is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Paracetamol IV is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Paracetamol IV is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Paracetamol IV players cover Mallinckrodt (Mallinckrodt Pharmaceuticals), Cipla Inc., Lupin, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Paracetamol IV Industry Forecast” looks at past sales and reviews total world Paracetamol IV sales in 2024, providing a comprehensive analysis by region and market sector of projected Paracetamol IV sales for 2025 through 2031. With Paracetamol IV sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Paracetamol IV industry.

This Insight Report provides a comprehensive analysis of the global Paracetamol IV landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Paracetamol IV portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Paracetamol IV market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Paracetamol IV and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Paracetamol IV.

This report presents a comprehensive overview, market shares, and growth opportunities of Paracetamol IV market by product type, application, key players and key regions and countries.

Segmentation by Type:
Pain
Pyrexia (Fever)

Segmentation by Application:
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mallinckrodt (Mallinckrodt Pharmaceuticals)
Cipla Inc.
Lupin
Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Novartis AG
Pfizer, Inc.
Abbott
Sanofi
Bristol-Myers Squibb Company

Please note: The report will take approximately 2 business days to prepare and deliver.